EV/EBITDA Ratio: 14.27x
Is the EV/EBITDA ratio high or low?
The EV/EBITDA ratio of 14.27x is 28% above its 5-year average of 11.16x, near the high end of its 5-year range (6.51x–14.90x).
As of Friday, June 26, 2026. 7.97% above its 12-month average of 13.22x.
DGX EV/EBITDA Ratio Chart
DGX Average EV/EBITDA Ratio Chart
DGX Current vs Average EV/EBITDA Ratio Chart
DGX EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
14.27x
EV/EBITDA RATIO AVG TTM
13.22x
EV/EBITDA RATIO AVG 3Y
12.93x
EV/EBITDA RATIO AVG 5Y
11.16x
EV/EBITDA RATIO AVG 10Y
11.44x
EV/EBITDA RATIO AVG 15Y
10.48x
EV/EBITDA RATIO AVG 20Y
10.11x
CURRENT VS TTM AVG
+7.97%
CURRENT VS 3Y AVG
+10.39%
CURRENT VS 5Y AVG
+27.91%
CURRENT VS 10Y AVG
+24.79%
CURRENT VS 15Y AVG
+36.22%
CURRENT VS 20Y AVG
+41.18%
DGX Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $23.08B | 14.27x | 13.22x | 12.93x | 11.16x |
| BioNTech SE (BNTX)vs › | $23.07B | N/A | 4.16x | 5.53x | 5.53x |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 16.09x | 13.31x | 11.35x | 12.46x |
| Incyte Corporation (INCY)vs › | $22.73B | 13.01x | 15.43x | 63.58x | 47.20x |
| Labcorp Holdings Inc. (LH)vs › | $22.10B | 12.61x | 14.33x | 15.99x | 12.60x |
| Waters Corporation (WAT)vs › | $24.41B | 37.64x | 22.33x | 21.78x | 21.91x |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.79B | 29.94x | 23.87x | 27.65x | 29.04x |
| STERIS plc (STE)vs › | $21.00B | 12.26x | 17.29x | 19.14x | 22.88x |
| Mettler-Toledo International Inc. (MTD)vs › | $25.44B | 21.50x | 23.41x | 23.62x | 26.25x |
| Moderna, Inc. (MRNA)vs › | $26.35B | N/A | 15.48x | 26.88x | 26.88x |
EV/EBITDA vs. its own history
At 14.3, EV/EBITDA is richer than usual, sitting higher than 99% of its 20-year history.
20-year low
6.1
median
9.5
20-year high
14.9
EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Quest Diagnostics Incorporated (DGX)?
- The EV/EBITDA ratio for DGX stock is 14.27x.
- Is Quest Diagnostics Incorporated's EV/EBITDA ratio high or low?
- The EV/EBITDA ratio of 14.27x is 28% above its 5-year average of 11.16x, near the high end of its 5-year range (6.51x–14.90x).
- What is the TTM average EV/EBITDA ratio for Quest Diagnostics Incorporated (DGX)?
- The TTM average EV/EBITDA ratio for DGX stock is 13.22x.
- What is the 3Y average EV/EBITDA ratio for Quest Diagnostics Incorporated (DGX)?
- The 3Y average EV/EBITDA ratio for DGX stock is 12.93x.
- What is the 5Y average EV/EBITDA ratio for Quest Diagnostics Incorporated (DGX)?
- The 5Y average EV/EBITDA ratio for DGX stock is 11.16x.
- What is the 10Y average EV/EBITDA ratio for Quest Diagnostics Incorporated (DGX)?
- The 10Y average EV/EBITDA ratio for DGX stock is 11.44x.
- What is the 15Y average EV/EBITDA ratio for Quest Diagnostics Incorporated (DGX)?
- The 15Y average EV/EBITDA ratio for DGX stock is 10.48x.
- What is the 20Y average EV/EBITDA ratio for Quest Diagnostics Incorporated (DGX)?
- The 20Y average EV/EBITDA ratio for DGX stock is 10.11x.
DGX EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-25 | 14.27x |
| 2026-06-24 | 14.10x |
| 2026-06-23 | 13.78x |
| 2026-06-22 | 13.58x |
| 2026-06-18 | 13.66x |
| 2026-06-17 | 13.81x |
| 2026-06-16 | 13.99x |
| 2026-06-15 | 14.05x |
| 2026-06-12 | 14.09x |
| 2026-06-11 | 14.14x |
| 2026-06-10 | 14.13x |
| 2026-06-09 | 14.17x |
| 2026-06-08 | 13.78x |
| 2026-06-05 | 13.94x |
| 2026-06-04 | 13.72x |
| 2026-06-03 | 13.59x |
| 2026-06-02 | 13.56x |
| 2026-06-01 | 13.51x |
| 2026-05-29 | 13.65x |
| 2026-05-28 | 13.72x |
| 2026-05-27 | 13.61x |
| 2026-05-26 | 13.55x |
| 2026-05-22 | 13.67x |
| 2026-05-21 | 13.60x |
| 2026-05-20 | 13.59x |
| 2026-05-19 | 13.41x |
| 2026-05-18 | 13.38x |
| 2026-05-15 | 13.21x |
| 2026-05-14 | 13.28x |
| 2026-05-13 | 13.44x |
| 2026-05-12 | 13.40x |
| 2026-05-11 | 13.38x |
| 2026-05-08 | 13.25x |
| 2026-05-07 | 13.44x |
| 2026-05-06 | 13.34x |
| 2026-05-05 | 13.44x |
| 2026-05-04 | 13.47x |
| 2026-05-01 | 13.53x |
| 2026-04-30 | 13.62x |
| 2026-04-29 | 13.35x |
| 2026-04-28 | 13.66x |
| 2026-04-27 | 13.75x |
| 2026-04-24 | 13.73x |
| 2026-04-23 | 13.90x |
| 2026-04-22 | 14.14x |
| 2026-04-21 | 13.83x |
| 2026-04-20 | 13.37x |
| 2026-04-17 | 13.30x |
| 2026-04-16 | 13.11x |
| 2026-04-15 | 13.11x |
| 2026-04-14 | 13.25x |
| 2026-04-13 | 13.19x |
| 2026-04-10 | 13.12x |
| 2026-04-09 | 13.45x |
| 2026-04-08 | 13.50x |
| 2026-04-07 | 13.39x |
| 2026-04-06 | 13.51x |
| 2026-04-02 | 13.46x |
| 2026-04-01 | 13.44x |
| 2026-03-31 | 13.35x |
| 2026-03-30 | 13.41x |
| 2026-03-27 | 13.33x |
| 2026-03-26 | 13.46x |
| 2026-03-25 | 13.38x |
| 2026-03-24 | 13.36x |
| 2026-03-23 | 13.33x |
| 2026-03-20 | 13.31x |
| 2026-03-19 | 13.25x |
| 2026-03-18 | 13.31x |
| 2026-03-17 | 13.49x |
| 2026-03-16 | 13.51x |
| 2026-03-13 | 13.55x |
| 2026-03-12 | 13.61x |
| 2026-03-11 | 13.59x |
| 2026-03-10 | 13.61x |
| 2026-03-09 | 13.64x |
| 2026-03-06 | 13.52x |
| 2026-03-05 | 13.77x |
| 2026-03-04 | 14.01x |
| 2026-03-03 | 14.00x |
| 2026-03-02 | 14.10x |
| 2026-02-27 | 14.19x |
| 2026-02-26 | 14.14x |
| 2026-02-25 | 14.08x |
| 2026-02-24 | 14.17x |
| 2026-02-23 | 14.06x |
| 2026-02-20 | 13.78x |
| 2026-02-19 | 13.79x |
| 2026-02-18 | 13.89x |
| 2026-02-17 | 13.95x |
| 2026-02-13 | 14.03x |
| 2026-02-12 | 14.02x |
| 2026-02-11 | 14.16x |
| 2026-02-10 | 13.94x |
| 2026-02-09 | 13.18x |
| 2026-02-06 | 13.15x |
| 2026-02-05 | 13.24x |
| 2026-02-04 | 13.07x |
| 2026-02-03 | 12.85x |
| 2026-02-02 | 12.84x |
| 2026-01-30 | 12.95x |
| 2026-01-29 | 12.70x |
| 2026-01-28 | 12.72x |
| 2026-01-27 | 12.80x |
| 2026-01-26 | 12.71x |
| 2026-01-23 | 12.63x |
| 2026-01-22 | 12.69x |
| 2026-01-21 | 12.82x |
| 2026-01-20 | 13.06x |
| 2026-01-16 | 13.09x |
| 2026-01-15 | 13.13x |
| 2026-01-14 | 12.94x |
| 2026-01-13 | 12.57x |
| 2026-01-12 | 12.35x |
| 2026-01-09 | 12.27x |
| 2026-01-08 | 12.45x |
| 2026-01-07 | 12.47x |
| 2026-01-06 | 12.60x |
| 2026-01-05 | 12.22x |
| 2026-01-02 | 12.24x |
| 2025-12-31 | 12.22x |
| 2025-12-30 | 12.33x |
| 2025-12-29 | 12.33x |
| 2025-12-26 | 12.35x |
| 2025-12-24 | 12.35x |
| 2025-12-23 | 12.31x |
| 2025-12-22 | 12.38x |
| 2025-12-19 | 12.36x |
| 2025-12-18 | 12.36x |
| 2025-12-17 | 12.52x |
| 2025-12-16 | 12.50x |
| 2025-12-15 | 12.80x |
| 2025-12-12 | 12.71x |
| 2025-12-11 | 12.66x |
| 2025-12-10 | 12.55x |
| 2025-12-09 | 12.55x |
| 2025-12-08 | 12.67x |
| 2025-12-05 | 12.71x |
| 2025-12-04 | 12.80x |
| 2025-12-03 | 12.71x |
| 2025-12-02 | 12.71x |
| 2025-12-01 | 12.78x |
| 2025-11-28 | 13.07x |
| 2025-11-26 | 13.10x |
| 2025-11-25 | 13.24x |
| 2025-11-24 | 13.14x |
| 2025-11-21 | 13.18x |
| 2025-11-20 | 12.98x |
| 2025-11-19 | 12.90x |
| 2025-11-18 | 12.86x |
| 2025-11-17 | 12.91x |
| 2025-11-14 | 12.95x |
| 2025-11-13 | 12.98x |
| 2025-11-12 | 12.94x |
| 2025-11-11 | 13.05x |
| 2025-11-10 | 12.81x |
| 2025-11-07 | 12.55x |
| 2025-11-06 | 12.38x |
| 2025-11-05 | 12.48x |
| 2025-11-04 | 12.47x |
| 2025-11-03 | 12.51x |
| 2025-10-31 | 12.35x |
| 2025-10-30 | 12.34x |
| 2025-10-29 | 12.29x |
| 2025-10-28 | 12.48x |
| 2025-10-27 | 12.59x |
| 2025-10-24 | 12.69x |
| 2025-10-23 | 12.75x |
| 2025-10-22 | 12.64x |
| 2025-10-21 | 12.82x |
| 2025-10-20 | 13.67x |
| 2025-10-17 | 13.62x |
| 2025-10-16 | 13.47x |
| 2025-10-15 | 13.50x |
| 2025-10-14 | 13.39x |
| 2025-10-13 | 13.24x |
| 2025-10-10 | 13.31x |
| 2025-10-09 | 13.17x |
| 2025-10-08 | 13.13x |
| 2025-10-07 | 13.19x |
| 2025-10-06 | 13.00x |
| 2025-10-03 | 13.05x |
| 2025-10-02 | 13.14x |
| 2025-10-01 | 13.20x |
| 2025-09-30 | 13.68x |
| 2025-09-29 | 13.58x |
| 2025-09-26 | 13.59x |
| 2025-09-25 | 13.39x |
| 2025-09-24 | 13.47x |
| 2025-09-23 | 13.48x |
| 2025-09-22 | 13.35x |
| 2025-09-19 | 13.29x |
| 2025-09-18 | 13.27x |
| 2025-09-17 | 13.21x |
| 2025-09-16 | 13.09x |
| 2025-09-15 | 13.12x |
| 2025-09-12 | 13.25x |
| 2025-09-11 | 13.28x |
| 2025-09-10 | 13.09x |
| 2025-09-09 | 13.23x |
| 2025-09-08 | 13.23x |
| 2025-09-05 | 13.28x |
| 2025-09-04 | 13.09x |
| 2025-09-03 | 13.06x |
| 2025-09-02 | 13.01x |
| 2025-08-29 | 13.18x |
| 2025-08-28 | 13.04x |
| 2025-08-27 | 13.07x |
| 2025-08-26 | 13.10x |
| 2025-08-25 | 13.01x |
| 2025-08-22 | 13.10x |
| 2025-08-21 | 13.29x |
| 2025-08-20 | 13.33x |
| 2025-08-19 | 13.24x |
| 2025-08-18 | 13.03x |
| 2025-08-15 | 13.07x |
| 2025-08-14 | 13.00x |
| 2025-08-13 | 13.03x |
| 2025-08-12 | 13.01x |
| 2025-08-11 | 12.99x |
| 2025-08-08 | 12.91x |
| 2025-08-07 | 12.76x |
| 2025-08-06 | 12.69x |
| 2025-08-05 | 12.71x |
| 2025-08-04 | 12.66x |
| 2025-08-01 | 12.57x |
| 2025-07-31 | 12.38x |
| 2025-07-30 | 12.45x |
| 2025-07-29 | 12.41x |
| 2025-07-28 | 12.40x |
| 2025-07-25 | 12.44x |
| 2025-07-24 | 12.63x |
| 2025-07-23 | 12.55x |
| 2025-07-22 | 13.89x |
| 2025-07-21 | 13.20x |
| 2025-07-18 | 13.22x |
| 2025-07-17 | 13.30x |
| 2025-07-16 | 13.23x |
| 2025-07-15 | 13.19x |
| 2025-07-14 | 13.31x |
| 2025-07-11 | 13.29x |
| 2025-07-10 | 13.49x |
| 2025-07-09 | 13.62x |
| 2025-07-08 | 13.55x |
| 2025-07-07 | 13.64x |
| 2025-07-03 | 13.82x |
| 2025-07-02 | 13.80x |
| 2025-07-01 | 13.96x |
| 2025-06-30 | 13.98x |
| 2025-06-27 | 13.87x |
| 2025-06-26 | 13.82x |
| 2025-06-25 | 13.92x |
| 2025-06-24 | 13.99x |
| 2025-06-23 | 13.98x |
| 2025-06-20 | 13.96x |
| 2025-06-18 | 13.98x |
| 2025-06-17 | 13.94x |
| 2025-06-16 | 14.12x |
| 2025-06-13 | 14.01x |
| 2025-06-12 | 13.94x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis